Actively Recruiting
Utilising Genotype Informed Bayesian Dosing of Tacrolimus in Children Post Solid Organ Transplantation.
Led by Murdoch Childrens Research Institute · Updated on 2026-02-25
45
Participants Needed
1
Research Sites
156 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study aims to evaluate the efficacy of genotype-informed Bayesian dosing of tacrolimus in optimising drug exposure among paediatric solid organ transplant recipients. By tailoring tacrolimus dosage based on individual genetic makeup and using Bayesian modeling to predict drug levels, the researchers hope to increase the likelihood of achieving therapeutic drug concentrations while minimising the risk of adverse events associated with subtherapeutic or supratherapeutic exposure.
CONDITIONS
Official Title
Utilising Genotype Informed Bayesian Dosing of Tacrolimus in Children Post Solid Organ Transplantation.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 1 to 18 years
- Kidney, liver, or heart transplant recipients
- Participant and/or parent consent to join the prospective study
You will not qualify if you...
- Previous liver transplant
- Lung or intestinal transplant
- Not enough time before transplant for genetic testing (prospective arm only)
- Immunosuppressant treatment does not include immediate release tacrolimus
- Known allergy or hypersensitivity to tacrolimus or its formulation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Royal Children's Hospital
Melbourne, Victoria, Australia, 3052
Actively Recruiting
Research Team
R
Rachel Conyers
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
SUPPORTIVE_CARE
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here